Mortier, V.; Wei, F.; Pellat, A.; Marchese, U.; Dohan, A.; Brezault, C.; Barat, M.; Fuks, D.; Soyer, P.; Coriat, R.
Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy. Cancers 2022, 14, 6179.
https://doi.org/10.3390/cancers14246179
AMA Style
Mortier V, Wei F, Pellat A, Marchese U, Dohan A, Brezault C, Barat M, Fuks D, Soyer P, Coriat R.
Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy. Cancers. 2022; 14(24):6179.
https://doi.org/10.3390/cancers14246179
Chicago/Turabian Style
Mortier, Victor, Felix Wei, Anna Pellat, Ugo Marchese, Anthony Dohan, Catherine Brezault, Maxime Barat, David Fuks, Philippe Soyer, and Romain Coriat.
2022. "Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy" Cancers 14, no. 24: 6179.
https://doi.org/10.3390/cancers14246179
APA Style
Mortier, V., Wei, F., Pellat, A., Marchese, U., Dohan, A., Brezault, C., Barat, M., Fuks, D., Soyer, P., & Coriat, R.
(2022). Impact of Sarcopenia on Patients with Localized Pancreatic Ductal Adenocarcinoma Receiving FOLFIRINOX or Gemcitabine as Adjuvant Chemotherapy. Cancers, 14(24), 6179.
https://doi.org/10.3390/cancers14246179